Faye Yu, BSc

Johnson & Johnson Innovative Medicine
Cambridge, Massachusetts, United States

Sr Scientist II Biomarkers

Presentation(s):

• 2297: Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients with Sjogren’s Disease Treated with Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study

  Tuesday, October 28, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): Johnson & Johnson Innovative Medicine: Employee (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)